<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:07:43 -0700</creation_date>
  <update_date>2013-01-15 20:07:43 -0700</update_date>
  <accession>HMDBP08208</accession>
  <secondary_accessions>
    <accession>13919</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>GABA(A) receptor subunit epsilon</synonym>
  </synonyms>
  <gene_name>GABRE</gene_name>
  <general_function>Involved in ion transport</general_function>
  <specific_function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00492</accession>
      <name>Chlorine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14332</accession>
      <name>Lorazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14686</accession>
      <name>Adinazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14939</accession>
      <name>Halazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15201</accession>
      <name>Clonazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15346</accession>
      <name>Estazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15512</accession>
      <name>Clotiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15513</accession>
      <name>Fludiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15526</accession>
      <name>Ketazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15527</accession>
      <name>Prazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15528</accession>
      <name>Quazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15533</accession>
      <name>Cinolazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba-a receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location/>
    <locus/>
    <gene_sequence>&gt;1521 bp
ATGTTGTCCAAAGTTCTTCCAGTCCTCCTAGGCATCTTATTGATCCTCCAGTCGAGGGTC
GAGGGACCTCAGACTGAATCAAAGAATGAAGCCTCTTCCCGTGATGTTGTCTATGGCCCC
CAGCCCCAGCCTCTGGAAAATCAGCTCCTCTCTGAGGAAACAAAGTCAACTGAGACTGAG
ACTGGGAGCAGAGTTGGCAAACTGCCAGAAGCCTCTCGCATCCTGAACACTATCCTGAGT
AATTATGACCACAAACTGCGCCCTGGCATTGGAGAGAAGCCCACTGTGGTCACTGTTGAG
ATCGCCGTCAACAGCCTTGGTCCTCTCTCTATCCTAGACATGGAATACACCATTGACATC
ATCTTCTCCCAGACCTGGTACGACGAACGCCTCTGTTACAACGACACCTTTGAGTCTCTT
GTTCTGAATGGCAATGTGGTGAGCCAGCTATGGATCCCGGACACCTTTTTTAGGAATTCT
AAGAGGACCCACGAGCATGAGATCACCATGCCCAACCAGATGGTCCGCATCTACAAGGAT
GGCAAGGTGTTGTACACAATTAGGATGACCATTGATGCCGGATGCTCACTCCACATGCTC
AGATTTCCAATGGATTCTCACTCTTGCCCTCTATCTTTCTCTAGCTTTTCCTATCCTGAG
AATGAGATGATCTACAAGTGGGAAAATTTCAAGCTTGAAATCAATGAGAAGAACTCCTGG
AAGCTCTTCCAGTTTGATTTTACAGGAGTGAGCAACAAAACTGAAATAATCACAACCCCA
GTTGGTGACTTCATGGTCATGACGATTTTCTTCAATGTGAGCAGGCGGTTTGGCTATGTT
GCCTTTCAAAACTATGTCCCTTCTTCCGTGACCACGATGCTCTCCTGGGTTTCCTTTTGG
ATCAAGACAGAGTCTGCTCCAGCCCGGACCTCTCTAGGGATCACCTCTGTTCTGACCATG
ACCACGTTGGGCACCTTTTCTCGTAAGAATTTCCCGCGTGTCTCCTATATCACAGCCTTG
GATTTCTATATCGCCATCTGCTTCGTCTTCTGCTTCTGCGCTCTGTTGGAGTTTGCTGTG
CTCAACTTCCTGATCTACAACCAGACAAAAGCCCATGCTTCTCCTAAACTCCGCCATCCT
CGTATCAATAGCCGTGCCCATGCCCGTACCCGTGCACGTTCCCGAGCCTGTGCCCGCCAA
CATCAGGAAGCTTTTGTGTGCCAGATTGTCACCACTGAGGGAAGTGATGGAGAGGAGCGC
CCGTCTTGCTCAGCCCAGCAGCCCCCTAGCCCAGGTAGCCCTGAGGGTCCCCGCAGCCTC
TGCTCCAAGCTGGCCTGCTGTGAGTGGTGCAAGCGTTTTAAGAAGTACTTCTGCATGGTC
CCCGATTGTGAGGGCAGTACCTGGCAGCAGGGCCGCCTCTGCATCCATGTCTACCGCCTG
GATAACTACTCGAGAGTTGTTTTCCCAGTGACTTTCTTCTTCTTCAATGTGCTCTACTGG
CTTGTTTGCCTTAACTTGTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>506</residue_number>
    <molecular_weight>57971.2</molecular_weight>
    <theoretical_pi>8.09</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>254-274</region>
      <region>281-301</region>
      <region>344-364</region>
      <region>486-506</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-22</region>
    </signal_regions>
    <protein_sequence>&gt;Gamma-aminobutyric acid receptor subunit epsilon
MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETE
TGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDI
IFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKD
GKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSW
KLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFW
IKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAV
LNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEER
PSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRL
DNYSRVVFPVTFFFFNVLYWLVCLNL</protein_sequence>
  </protein_properties>
  <genbank_protein_id>1857126</genbank_protein_id>
  <uniprot_id>P78334</uniprot_id>
  <uniprot_name>GBRE_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>U66661</genbank_gene_id>
  <genecard_id>GABRE</genecard_id>
  <geneatlas_id>GABRE</geneatlas_id>
  <hgnc_id>HGNC:4085</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Davies PA, Hanna MC, Hales TG, Kirkness EF: Insensitivity to anaesthetic agents conferred by a class of GABA(A) receptor subunit. Nature. 1997 Feb 27;385(6619):820-3.</reference_text>
      <pubmed_id>9039914</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wilke K, Gaul R, Klauck SM, Poustka A: A gene in human chromosome band Xq28 (GABRE) defines a putative new subunit class of the GABAA neurotransmitter receptor. Genomics. 1997 Oct 1;45(1):1-10.</reference_text>
      <pubmed_id>9339354</pubmed_id>
    </reference>
    <reference>
      <reference_text>Garret M, Bascles L, Boue-Grabot E, Sartor P, Charron G, Bloch B, Margolskee RF: An mRNA encoding a putative GABA-gated chloride channel is expressed in the human cardiac conduction system. J Neurochem. 1997 Apr;68(4):1382-9.</reference_text>
      <pubmed_id>9084408</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Lahti RA, Sethy VH, Barsuhn C, Hester JB: Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology. 1983 Nov;22(11):1277-82.</reference_text>
        <pubmed_id>6320036</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Sethy VH, Collins RJ, Daniels EG: Determination of biological activity of adinazolam and its metabolites.  J Pharm Pharmacol. 1984 Aug;36(8):546-8.</reference_text>
        <pubmed_id>6148400</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Iorio LC, Barnett A, Billard W: Selective affinity of 1-N-trifluoroethyl benzodiazepines for cerebellar type 1 receptor sites. Life Sci. 1984 Jul 2;35(1):105-13.</reference_text>
        <pubmed_id>6738302</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halazepam</name>
        <accession>HMDB14939</accession>
      </metabolite>
      <reference>
        <reference_text>Wamsley JK, Golden JS, Yamamura HI, Barnett A: Autoradiographic demonstration of the selectivity of two 1-N-trifluoroethyl benzodiazepines for the BZD-1 receptors in the rat brain. Pharmacol Biochem Behav. 1985 Dec;23(6):973-8.</reference_text>
        <pubmed_id>2867566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Braestrup C, Squires RF: Pharmacological characterization of benzodiazepine receptors in the brain.  Eur J Pharmacol. 1978 Apr 1;48(3):263-70.</reference_text>
        <pubmed_id>639854</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Miller LG, Greenblatt DJ, Barnhill JG, Deutsch SI, Shader RI, Paul SM: Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. J Neurochem. 1987 Nov;49(5):1595-601.</reference_text>
        <pubmed_id>2889803</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clotiazepam</name>
        <accession>HMDB15512</accession>
      </metabolite>
      <reference>
        <reference_text>Mandrioli R, Mercolini L, Raggi MA: Benzodiazepine metabolism: an analytical perspective.  Curr Drug Metab. 2008 Oct;9(8):827-44.</reference_text>
        <pubmed_id>18855614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fludiazepam</name>
        <accession>HMDB15513</accession>
      </metabolite>
      <reference>
        <reference_text>Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.</reference_text>
        <pubmed_id>2857046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazepam</name>
        <accession>HMDB15527</accession>
      </metabolite>
      <reference>
        <reference_text>Schove LT, Perez JJ, Loew GH: Molecular determinants of recognition and activation at the cerebellar benzodiazepine receptor site. Bioorg Med Chem. 1994 Oct;2(10):1029-49.</reference_text>
        <pubmed_id>7773620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy.  Epilepsia. 1986;27 Suppl 1:S3-13.</reference_text>
        <pubmed_id>3017690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87.</reference_text>
        <pubmed_id>2892106</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinolazepam</name>
        <accession>HMDB15533</accession>
      </metabolite>
      <reference>
        <reference_text>Walash MI, Belal F, Metwally ME, Hefnawy MM: A selective fluorimetric method for the determination of some 1,4-benzodiazepine drugs containing a hydroxyl group at C-3. J Pharm Biomed Anal. 1994 Nov;12(11):1417-23.</reference_text>
        <pubmed_id>7849137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
